The low-density lipoprotein receptor (LDLR) 
Introduction
Hepatitis C is a disease with a worldwide prevalence of approximately 3%. 1 An estimated 80% of individuals infected by the hepatitis C virus (HCV) develop persistent infection, and these patients are likely to develop chronic liver disease leading to cirrhosis and/or cancer of the liver. 2 The rate of disease progression varies widely and it is not known what precisely determines the clinical outcome of the disease long term. Furthermore, the mechanism of viral entry into the host hepatocyte is unknown.
In recent years many efforts have been made to identify receptors involved in viral entry into host cells. Two molecules have been proposed to function as HCV receptors, namely the low density lipoprotein receptor (LDLR) and CD81. [3] [4] [5] The LDLR gene family has been shown to function as a receptor for the minor-group common cold virus and for the subgroup A Rous sarcoma virus previously. 6, 7 The LDLR is known to play an important role in cholesterol homeostasis and lipid transport by mediating the cellular uptake of plasma LDL. 8, 9 It has been firmly established that mutations and polymorphisms in the LDLR gene are associated with familial hypercholesterolemia (FH), obesity and atherosclerosis. [10] [11] [12] FH is an autosomal dominant inherited condition charac-terized by raised levels of LDL-cholesterol leading to increased risk of coronary heart disease. Changes in lipid metabolism during the acute phase response in the liver due to infection and inflammation also suggest the involvement of the lipoprotein system in innate immune responses. 13 CD81 is a member of the tetraspanin or transmembrane 4 superfamily (TM4SF) and like other members of its family is involved in signal transduction, cell-cell adhesion and cellular activation or development. 14 In particular, the large extracellular loop (LEL) of the CD81 molecule appears to be involved in the binding between HCV envelope glycoprotein E2 and CD81. 5, 15 Thus, CD81 is thought to play a role in HCV endocytosis, although receptor downregulation after binding has not been observed.
The outcome of a large number of infectious diseases is affected by a multitude of factors including environmental factors, interactions with pathogens and host factors, particularly genetic variability. Disease association studies based on polymorphisms are widely used in the elucidation of host genetic factors influencing multifactorial diseases and may help in identifying individuals at risk of developing a disease or a specific disease outcome. 16 The clinical outcome of hepatitis C infection and response to current treatment is variable and remains poorly understood. Only approximately 20-30% of infected individuals will spontaneously clear the virus (self-limiting infection), whereas the remaining 70-80% proceed to chronic HCV infection. 2 If treated, patients generally now receive a combination therapy with interferon-␣ and Ribavirin for 6 or 12 months. Patients can be classified into three groups according to the response. Sustained responders (SR) are those who have normal liver transaminases and undetectable viraemia 6 months after completion of therapy. Relapsers (RL) are those who initially respond to treatment but at 6 months post-treatment viraemia has recurred. Non-responders (NR) are those patients who never lose their viraemia. 17 Chronic hepatitis C is characterised by varying degrees of hepatic inflammation and fibrosis. Approximately one-third of carriers will develop cirrhosis and/or cancer of the liver in the long term. 18 The degree of inflammation, the severity of fibrosis and response to therapy are likely to be influenced by host factors. Increasing research activity focuses on the elucidation of host genetic factors affecting disease progression in hepatitis C. 19, 20 Case-control studies have identified associations with HCV persistence and polymorphisms in histocompatibility antigens (HLA), 20, 21 cytokine genes such as TNF-␣, IL-10 and TGF-␤1 [22] [23] [24] as well as the hemochromatosis (HFE) gene [25] [26] [27] have been correlated with parameters of HCV infection.
Due to its proposed function as receptor for HCV, its role in immune responses and the presence of known polymorphisms, the LDLR provides an important candidate for the study of genetic susceptibility to hepatitis C. We report here on the investigation of nine single nucleotide polymorphisms (SNPs) in the LDLR gene and their possible influence on clinical parameters of HCV infection in a case-control study. Specifically, we genotyped SNPs in the promoter region, exons 2, 8, 10, 12, 13; intron 15 and the 3ЈUTR (see Figure 1 ). Possible associations between genetic variation and viral clearance, overall inflammation, severity of fibrosis and response to treatment were assessed. In addition we report on the screening of the coding region of the putative HCV co-receptor, CD81, for polymorphisms that might affect the binding affinity between CD81 and virus particles.
Results

Patient's characteristics
In the current study a total number of 837 HCV patients was available. The sex was known for 599 (71.6%) patients, the sex ratio was 54.8% male to 45.2% females. We had data on ethnicity for 583 (69.7%) of patients; 91% of these were of white Caucasian, 5.5% of Asian and 4.5% of Afro-Caribbean origin, respectively. Both sex and ethnicity were accounted for by logistic regression. Age data was available for 385 (46.0%) patients, covering an age range of 18 to 84 years. 87% of patients with known age were Ͻ40 and the remaining 13% Ͼ40 years old. Taking the age cut-off of 40 years 28 into account by logistic regression in addition to sex and ethnicity halved the numbers of samples available for the analysis and thus drastically reduced the statistical power, although the odds ratio (OR) for the associations between genotype and disease parameters observed did not change significantly (data not shown). Furthermore, genotype frequencies for all seven SNPs investigated did not vary significantly between different age groups (0-20, 21-40, 41-60 and Ͼ60 years, data not shown). Interferon response data was available for 50.4% of patients with persistent HCV infection. However, data on regime of anti-viral treatment (IFN monotherapy or combination treatment) was only obtainable for a subset of these, comprising 110 samples. Similarly, viral genotype was available for a limited number of patients (n = 180); in this subgroup we observed viral genotypes 1, 2, 3, 4 and 5 with a frequency of 63.4, 9.4, 23.3, 3.3 and 0.6%, respectively. Due to the limitations of our data with respect to age, type of anti-viral therapy and viral genotype we did not account for these factors in the analysis, however, we corrected for sex and ethnicity by logistic regression.
Genotyping analysis in LDLR
All available genotype data was analysed with respect to the following comparisons: self-limiting vs persistent HCV infection; treatment responders (SR) vs nonresponders (NR); sustained treatment responders and relapsers (RL) combined vs non-responders; mild vs severe fibrosis; and mild vs severe inflammation (as measured by necro-inflammatory score). Table 1 shows a summary of overall P-values for all SNPs tested, corrected for ethnicity and sex by logistic regression. The number of samples available for each comparison is given in parentheses. Table 2 gives the results for presence/absence of specific genotypes and alleles, with the risk associated with carriage of specific alleles given as an OR.
Two SNPs in the promoter region were shown to be monomorphic in our population. The codon change in exon 8 at position 11429 (Ala/Thr) was found to be associated with severity of fibrosis (P = 0.022, 2 = 7.676). This is due to an increased frequency of the G allele (Ala), Table 2 shows the results for the genotype distribution for all SNPs investigated with overall P-values and number of individuals analysed in each clinical category in parentheses. All results were corrected for ethnic origin and sex by logistic regression. A P value of Ͻ0.05 was considered as significant and significant results are shown in bold. Table 3 shows the results for the genotype frequencies, Hardy-Weinberg-equilibrium (HWE) and presence/absence of specific genotypes for SNPs that showed a significant overall genotype distribution. All data was corrected for sex and ethnicity by logistic regression. Odds ratio (OR) and 95% CI indicate the risk associated with the carriage of specific alleles.
rendering patients carrying this allele more susceptible to severe fibrosis (OR 2.68). The exon 8 polymorphism furthermore showed borderline significance with overall inflammation with a potentially beneficial effect of heterozygote status (OR 0.43). The G → A change at position 13397 in exon 10 was shown to be associated with viral clearance (P = 0.013, 2 = 8.653), which appears to be a heterozygote effect. The SNP in exon 10 furthermore showed a correlation with overall inflammation (P = 0.025, 2 = 7.364). Upon stratification of the alleles it was shown that the frequency of the G allele is higher in patients with a necro-inflammatory score Ͻ5, carriage of this allele thus appears to have a protective effect (OR 0.31). The SNP in the 3ЈUTR was correlated with response to treatment (P = 0.023, 2 = 7.560). Presence of the G allele was increased in the sustained responder + relapser group, indicating that individuals carrying the G allele are more likely to respond to treatment than those carrying the A allele (OR 3.58). There were no other significant results between any of the SNPs studied and the clinical parameters of HCV infection.
Linkage disequilibrium (LD) across LDLR locus
The analysis of LD was carried out using the GOLD programme and included all SNPs studied, except for the two promoter SNPs, spanning a region of approximately 32 kb. The following pairwise combinations were shown to be in significant LD: exons 2 and 10 (DЈ = 0.532, P = 0.00834); exon 2 and intron 15 (DЈ = 0.894, P Ͻ 0.0001); exons 10 and 13 (DЈ = 0.534, P Ͻ 0.0001); exons 12 and 13 (DЈ = 0.528, P Ͻ 0.0001); intron 15 and 3ЈUTR (DЈ = 0.820, P Ͻ 0.0001).
LDLR haplotype analysis
A total of 25 haplotypes was observed in a subgroup of samples (n = 91) for which data of all SNPs was available (excluding the two promoter SNPs). Three of these are relatively common with a frequency of Ͼ10%. Haplotypes that were present with a frequency of more than 5% are listed in Table 3 . A common pattern for haplotypes appearing with a frequency of Ͼ5% was seen with the haplotype C-A-G-(T/C)-(T/C)-G-G comprising a collective frequency of 64.28%.
CD81 sequencing
The coding region of the CD81, including exons 5 to 7 which encode the large extracellular loop, was found to 
100.00 Table 4 lists haplotypes of Ͻ5% frequency obtained from 91 individuals for which genotyping data for all SNPs analysed was available. A total of 25 haplotypes was identified in this patient cohort (data not shown). A common pattern for haplotypes appearing with a frequency of Ͼ5% was seen with the haplotype C-A-G-(T/C)-(T/C)-G-G comprising a collective frequency of 64.28%.
be highly conserved in the 35 patients sequenced, indicating that novel polymorphisms were not present in this region.
Discussion
Genetic variation in the LDLR gene has been studied intensively over the past two decades or more. Most research has concentrated on the involvement of LDLR defects in FH but, more recently, the analysis of LDLR polymorphisms has been applied to the study of obesity, atherosclerosis and HIV infection. 11, 12, 29, 30 The data reported here provides evidence for an involvement of LDLR polymorphism in the pathogenesis and/or progression of hepatitis C. Within the LDLR gene there are abundant polymorphisms, which have been well characterized and studied intensively (details found at http://www.ucl.ac.uk/fh). For the present study we selected nine SNPs as shown in Figure 1 , based on likely functionality and reported prevalence.
We showed a negative correlation between the SNP in exon 8 and severity of fibrosis as well as a protective effect on inflammation. Correlations were seen between the SNP in exon 10 and viral clearance as well as inflammation and finally an association between the SNP in the 3ЈUTR and response to treatment. Of these only the polymorphism in exon 8 leads to an amino acid change from alanine to threonine. In our population carriage of the G allele (Ala) for this polymorphism appeared to render patients more susceptible to develop severe fibrosis (OR 2.68). Heterozygocity at this SNP appeared to have a protective effect against inflammation (OR 0.43), as it did at the SNP in exon 10 with respect to viral persistence (OR 0.46). Heterozygous effects are difficult to interpret and it may be that these results have arisen by chance as the P-values of 0.014 and 0.041 respectively become non-significant if corrected for the number of multiple comparisons. Borderline significance was also found with carriage of the G allele for the exon 10 polymorphism and association with severity of inflammation (OR 0.31). Finally, patients carrying the G allele at the SNP in the 3ЈUTR were shown to be less likely to respond to interferon therapy than those carrying the A allele (OR 3.58). Neither SNP in exon 10 or in 3ЈUTR lead to amino acid changes; however, the significant association of these SNPs with disease progression in hepatitis C indicate that they may lie in LD with other 363 polymorphisms within this locus. We have thus assessed the LD across the LDLR locus including data available for all SNPs under investigation from 91 individuals and covering a region of approximately 32 kb. The two promoter SNPs at positions −175 and −124 sites proved to be monomorphic in our population and were thus excluded from all further analyses. We demonstrate a complex pattern of LD across the region and strong pairwise LD (DЈ Ͼ0.5, P Ͻ 0.001) was observed between the SNPs in exons 2 and 10; exon 2 and intron 15, exons 10 and 13; exons 12 and 13 and intron 15 and the SNP in the 3ЈUTR, respectively. This shows that the three polymorphisms we found to be associated with disease progression are in LD with other SNPs within the gene. Considering that we have covered the whole length of the LDLR locus it seems that there is no single polymorphism exerting a major effect upon disease. It is unlikely that there is another SNP with a major effect upon hepatitis C infection that would not be in LD with the SNPs studied here. Since the polymorphism in exon 8 is a codon change and it shows the strongest association with severity of fibrosis, this is the most likely SNP to have a causative effect upon disease progression. Our data analysis was limited by the availability of information on potentially confounding factors such as age, viral genotype, regime of anti-viral treatment and steatosis. Polymorphisms in the LDLR gene may theoretically affect steatosis, which is fatty deposition in the liver, and an effect of steatosis on progression of severe liver disease has been proposed, but remains unclear. In the absence of a scoring system for steatosis it was unmanageable to assess the possible interaction between LDLR genotypes, steatosis and persistent HCV infection in our cohort. However, possible influences of sex and ethnicity were corrected for. In particular LDLR genotype frequencies have been shown to vary substantially in different populations, indicating genetic heterogeneity even within Europe. [31] [32] [33] The SNP in exon 2 at position 39 leads to an amino acid change from alanine to serine. To our knowledge this polymorphism has not been shown to have an involvement with any disease to date. The codon change in exon 8 has been associated with raised levels of total plasma cholesterol and LDL-cholesterol and apoB in men. 34 Vector expression experiments have shown that there was no difference in the production of LDL receptors or its activity from vectors carrying the alanine or threonine sequence, although a minor influence on receptor activity was not excluded. The polymorphism in exon 10 does not lead to an amino acid change. However, it has been shown that the G allele of this SNP cosegregated with elevated LDL cholesterol without exception in a Japanese pedigree. 35 The silent change in exon 12 has been shown to be associated with altered concentrations of total and LDL cholesterol in FH studies. 31, 33 Another study showed that this SNP was associated with obesity overall, but not with plasma lipid levels. 11 The C → T changes in exon 13 and in intron 15 have both been associated with disease pathogenesis in FH, although some reports are inconsistent. 32, 36, 37 Finally, the G→A transition in 3ЈUTR is located 56 bp downstream of the termination codon; its potential function is unclear.
The LDLR has been proposed as the viral receptor for HCV and other flaviviridae. This hypothesis has been based on the following evidence: in vitro studies showed that HCV-RNA-carrying material bound to lipoproteins
Genes and Immunity and immunoglobulins, and HCV binding to human fibroblasts could be initiated with purified LDL. 4 Since LDL is internalized by LDLR it was presumed that HCV in turn could be internalized by LDLR-mediated endocytosis. It has been shown that the endocytosis of viral particles is associated with LDLR activity, based upon the correlation of cells positive for HCV and for LDLR. 38 Furthermore, continued stimulation of LDLR expression enhanced virus replication in vitro. 39 The serum concentration of beta-lipoproteins is thought to influence HCV concentration, as the former could inhibit the binding of the virus to its proposed receptor, the LDLR. Indeed, it was demonstrated that beta-lipoproteins negatively affected the level of HCV-Ag. 40 Studies using HCV pseudotype viruses support the hypothesis that LDLR, CD81 and heparin are involved in HCV cell entry. 41 Another study identified a LDLR-related molecule from Caenrohabditis elegans that was capable of binding to a complex of E1-E2 HCV envelope protein. 42 Additionally, a soluble form of the LDLR has been described as a potent antiviral protein against vesticular stomatitis virus. 43 It contains only the ligand binding domain of the LDLR, is interferon-induced, secreted extracellularly and appears to interfere with viral replication. It was proposed that the production of soluble variants by host cells may be employed in order to control virus infections. Overall it remains uncertain as to whether virus uptake can be mediated directly by the LDLR, but lipoprotein bound to HCV may function as a ligand. It thus seems the LDLR or its homologues are involved in endocytosis of HCV, however, the exact mechanisms underlying this process are to date not fully understood. Therefore, polymorphisms in the LDLR could influence the activity of the receptor and thus may affect the level of cellular entry for HCV. This in turn may influence the ability of the virus to establish persistent infection, to evade interferon therapy and to induce liver fibrosis.
There is also compelling evidence for the involvement of components of the lipoprotein system in innate immunity, the primary defense against microorganisms such as HCV. Lipoproteins may be involved in the redistribution of nutrients, neutralisation, binding or lysis of viruses and the binding of endotoxins and other biological agents. 44 Indeed, it has been shown that high lipoprotein levels reduce cytokine responses, 45 increase macrophage chemotaxis 46 and impair antiviral T cell immunity in hypercholcholesterolemic LDLR deficient mice. 47 It is hence plausible that genetic variation in the LDLR gene could affect the immune responses in HCV infection.
A further molecule that has been proposed as a receptor mediating the uptake of HCV into hepatocytes is the cell membrane protein CD81. 5 In particular the large extracellular loop (LEL), but not the small extracellular loop, of the CD81 protein has been shown to be critical for the interaction with HCV E2 envelope protein. 15, 48 We sequenced all exons of the CD81 gene in order to identify novel polymorphisms that may affect the protein binding affinity, in particular the region spanning exons 5 to 7, which encodes the LEL. However, we did not find any SNPs within the coding region of this locus in the 35 HCV patients sequenced. We thus showed that there is no genetic variation in this region that could affect the binding of virus particles and therefore susceptibility to HCV infection. This does not rule out the mediation of viral uptake through CD81 as such, or the role of polymorphisms in other regulatory regions of the gene upon this process. However, no polymorphisms were found in CD81 cDNA sequence from a Japanese cohort consisting of 24 individuals, and although sequence variation was detected in the 3Ј and 5Ј non-coding regions, it was considered unlikely that CD81 would influence the progression of chronic hepatitis. 49 It thus seems doubtful that CD81 is the only cell surface receptor for HCV and indeed, it has been shown that CD81 has a poor capacity to mediate virus entry into hepatocytes. 50 In summary, it appears that variants in the LDLR gene, which influence the pathogenesis of FH and related diseases, may contribute to variation in severity of fibrosis, inflammation and response to treatment in hepatitis C. There is a complex interaction between IFN-␣ and LDLR activity, which could play an important role in these processes. LDLR activity appears to be increased by IL-1, 51 which is downregulated by its receptor antagonist, IL-1RA. 52 Circulating IL-1RA in turn has been shown to be induced by IFN treatment. 53, 54 IFN-␣ may therefore indirectly suppress LDLR activity by increasing secretion of IL-1 receptor antagonist production and thus decreasing IL-1 receptor-mediated stimulation by IL-1. 3 Taking our findings into account we thus hypothesise that LDLR polymorphisms may have an influence upon disease progression rather than viral clearance, ie, our findings support a role in immune response modulation rather than the LDLR functioning as entry receptor for HCV as such. However, it is important to note the limitation of our data analysis with respect to confounding factors other than sex and ethnicity. Overall, our data add to the increasing body of evidence of the involvement of host genetic factors in infectious disease and hepatitis C infection in particular. Similar studies should be conducted in other population in order to confirm, or otherwise, these findings.
Materials and methods
Patients
Participants for this study were recruited at several large hepatology clinics in Greece, Spain, Germany, Sweden, France, Italy and the UK between October 1995 and February 2001. Patients were categorized on the basis of viral serology, liver histology and response to treatment. Exclusion criteria included co-infection with hepatitis B virus or HIV. All patients included were positive for HCV antibody (ELISA2 assay, Abbot Laboratories Ltd, Maidenhead, UK) and had no evidence of liver disease due to other causes. Patients classified as having a persistent infection were HCV antibody positive and PCR positive for Ͼ6 months post presentation or likely time of infection. Patients with a self-limiting infection showed normal concentrations of liver aminotranferase enzymes; they were HCV antibody positive and PCR negative at presentation on at least one occasion Ͼ3 months later.
The response to combined interferon-␣ and Ribavirin or interferon-␣ therapy alone was evaluated in patients who had received treatment for Ͼ3 months. SRS were defined as individuals with normal concentrations of liver aminotransferases and no detectable viraemia Ͼ6 months after the course of drug administration. Nonresponders (NR) were defined as patients with continuous viraemia Ͼ3 months into therapy. Relapsers (RL) were those patients with non-detectable viraemia, using the Roche Amplicor test (Roche Diagnostics, Lewes, UK) with a lower end sensitivity of 200 genomes per ml, during the course of treatment and detectable viraemia following the end of the drug administration.
Overall inflammation was scored according to the modified histological activity index (HAI-Ishak) for liver histology. 55 Patients were divided into two groups, those with a necro-inflammatory score of Ͻ5 (mild) or Ͼ5 (severe), respectively. The severity of fibrosis was also assessed by liver histology, scoring according to the Ishak's system. Patients with persistent infection were divided into those with a fibrosis score of Ͻ2 (mild) or Ͼ3 (severe) at the time of presentation. Further details of the patient criteria are reported by Thursz et al.
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Genotyping Sample genotypes were analyzed by the ligation detection reaction (LDR). 56 Briefly, PCR products containing the SNP of interest were generated under standard conditions in a 15 l reaction containing 1× reaction buffer, 1-2 mM MgCl 2 , 0.32 mM dNTP (all reagents Perkin Elmer Applied Biosystems, Warrington, UK), 0.12 M of forward (F) and reverse (R) primer respectively, 1 unit Taq polymerase, 50 ng DNA and dH 2 O). Cycling parameters were 94°C for 14 min followed by 35 cycles of 94°C for 30 sec, the specified annealing temperature (see below) for 30 sec and 72°C for 30 sec, followed by a final step of 72°C for 5 min. For PCR primer sequences, PCR annealing temperatures and PCR product sizes refer to Table 4 . PCR reactions were treated with 1.5 l of 1 mg/ml proteinase K (in 50 mM EDTA) in one cycle of 37°C for 15 min, 55°C for 10 min and 90°C for 10 min to destroy any remaining DNA polymerase activity prior to LDR amplification.
For genotyping by the LDR method, three oligonucleotide probes are required for each SNP. These comprise two allele specific probes labeled with a different fluorescent tag at the 5Ј end and the allele specific base at the 3Ј end as well as a phosphorylated unlabelled common probe. The phosphorylation is carried out in a 100 l reaction containing 2 M of the common probe, 250 M ATP, 1× Polynucleotide kinase buffer and 1 l Polynucleotide kinase (all reagents Promega) and incubated at 37°C for 45 min. To this mix 100 l of proteinase K (0.2 mg/ml in TE, pH 8.0) were added and the reaction incubated at 37°C for a further 30 min prior to increasing the incubation temperature to 90°C for 10 min. All probes were designed using the TM calc function in the Bench Mate programme under nearest neighbour conditions (http://biochem.roche.com/benchmate). If required the length of probes was adjusted by adding poly A's, these were not complementary to the sequence and did not affect the TM. Each 15 l LDR reaction typically contained 1× Taq Ligase Buffer (New England Biolabs Ltd, Hitchin, UK), 0.2 M of phosphorylated common probe, 0.067 M of each of the allelic probes, 1 l of PCR product, 10 units of Taq DNA Ligase (New England Biolabs) and dH 2 O. LDR reactions for up to five SNPs could be pooled in one reaction. The LDR reactions were cycled as follows: 95°C for 1 min followed by 15 cycles at 95°C for 15 sec and the appropriate annealing temperature for 4 min. To prevent any further ligase activity samples were treated with 3 l of 100 mM EDTA. Further details Table 4  Table 4 regarding the LDR reactions can be found in Table 4 . Finally, 1 l of each LDR amplification product was run on an ABI prism 373 sequencer (Perkin Elmer Applied Biosystems, Warrington, UK) and sample genotypes analysed using GENESCAN and Genotyper software programmes (Perkin Elmer Applied Biosystems).
Statistical analysis
The distribution of genotype and allele frequencies was analyzed using standard 3 × 2 or 2 × 2 2 tests or Fisher's exact tests applying SPSS 9.0 for Windows or the Statcalc programme (Epi2000, Centre for Disease Control and Prevention, Atlanta, Georgia, USA; http://www.cdc. gov/epiinfo/index.htm). A value of P Ͻ 0.05 was considered as significant. The OR was calculated to indicate the risk associated for individual alleles with 95% confidence intervals (CI). The potentially confounding effects of ethnic group and sex were corrected for by logistic regression.
Linkage disequilibrium analysis LD analysis was performed using GOLD software (graphical overview of LD; http://www.well.ox.ac.uk/ asthma/GOLD/ 57 ). Significant LD was defined here as a DЈ value of Ͼ0.5 and a P-value of Ͻ0.05.
Haplotype analysis
Haplotype analysis was carried out using the PHASE software programme (version 0.21, http://www.stats. ox.ac.uk/mathgen/software.html 58 ). . Twenty l PCR and sequencing reactions were run under standard conditions. Sequencing was performed using an AB1377 sequencer and each exon was sequenced in both directions.
Sequencing analysis
